BiotechTube
Kernal Biologics

Kernal Biologics

San Diego, United States· Est.
kernalbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $29.3M

Overview

Kernal Biologics is developing a next-generation mRNA platform designed to overcome key limitations of current cell therapies by programming cells directly inside the body (in vivo). Its core innovation lies in two pillars: precise tissue/cell targeting using engineered LNPs to avoid liver sequestration, and AI-programmed selective mRNA translation to minimize off-target effects. The company is advancing a pipeline of in vivo CAR-T therapies for solid tumors and autoimmune disorders, backed by significant non-dilutive funding including a recent award from ARPA-H.

OncologyAutoimmune Diseases

Technology Platform

Proprietary 'mRNA 2.0' platform combining AI-driven design for cell-selective mRNA translation with antibody-decorated lipid nanoparticles (LNPs) for targeted in vivo delivery to tissues beyond the liver.

Funding History

2
Total raised:$29.3M
Series A$25M
Seed$4.3M

Opportunities

The shift from ex vivo to in vivo cell therapy represents a massive market opportunity to reduce cost, complexity, and wait times for patients, potentially expanding access to CAR-T treatments for solid tumors and autoimmune diseases.
Non-dilutive funding from ARPA-H provides significant capital to de-risk the platform and advance toward clinical trials.
The company's targeted LNP technology could have broad utility beyond its initial CAR-T focus, enabling partnerships or new programs.

Risk Factors

The platform is highly complex and unproven in humans, with significant technical risk in achieving both precise delivery and selective translation simultaneously.
As a preclinical-stage company, Kernal faces a long, costly, and uncertain path to clinical validation.
Competition in the in vivo cell engineering space is intense from both biotech startups and large pharmaceutical companies with substantial resources.

Competitive Landscape

Kernal operates in the competitive and rapidly evolving field of in vivo cell therapy and targeted mRNA delivery. Key competitors include other biotechs developing in vivo CAR-T platforms (e.g., Capstan Therapeutics, Umoja Biopharma, Ensoma) and companies advancing targeted LNPs for RNA delivery. Large pharma companies like Pfizer, Moderna, and Roche are also investing heavily in next-generation mRNA and cell therapy technologies, posing both competitive and partnership opportunities.

More companies in mRNA Therapeutics →More companies in United States →